priors.science/reviews/targeted-therapy-lung-cancer

Targeted Therapy Lung Cancer

The current evidence on 13 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

13claims tracked
119primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
6 Established · 7 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Alectinib first-line for ALK-positive non-small cell lung cancerALKEstablished92%10
Osimertinib first-line for EGFR-mutant lung cancerEGFREstablished91%12
Lorlatinib third-line for ALK-positive lung cancerALKEstablished90%9
Adjuvant osimertinib in resected EGFR-mutant lung cancerEGFREstablished90%10
Osimertinib second-line for EGFR T790M resistanceEGFR ResistanceEstablished90%8
Selpercatinib for RET fusion non-small cell lung cancerMet RetEstablished88%9
Larotrectinib and entrectinib for NTRK fusion cancersBraf NtrkLikely84%9
Sotorasib for KRAS G12C non-small cell lung cancerKrasLikely83%9
Adagrasib for KRAS G12C non-small cell lung cancerKrasLikely83%8
Capmatinib and tepotinib for MET exon 14 skipping lung cancerMet RetLikely82%10
Dabrafenib plus trametinib for BRAF V600E non-small cell lung cancerBraf NtrkLikely79%8
EGFR C797S-mediated osimertinib resistanceEGFR ResistanceLikely78%8
Amivantamab for EGFR exon 20 insertion lung cancerEGFRLikely72%9
Track Targeted Therapy Lung Cancer.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.